Kezar Life Sciences

About:

Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders

Website: https://kezarlifesciences.com/

Top Investors: Qiming Venture Partners, Cormorant Asset Management, EcoR1 Capital, Cowen Group, Morningside Venture Investments

Description:

Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential.

Total Funding Amount:

$135M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

South San Francisco, California, United States

Founded Date:

2015-01-01

Contact Email:

contact(AT)kezarbio.com

Founders:

Christopher Kirk, Jack Taunton, John Fowler

Number of Employees:

51-100

Last Funding Date:

2022-10-03

IPO Status:

Public

Industries:

© 2025 bioDAO.ai